GSK993

GSK993 is a small molecule inhibitor developed by GSK that targets stearoyl-CoA desaturase 1 (SCD1), an enzyme involved in the biosynthesis of monounsaturated fatty acids from saturated fatty acids. SCD1 has emerged as a therapeutic target for metabolic disorders such as obesity and insulin resistance due to its role in lipid metabolism. In preclinical studies, GSK993 demonstrated potent and orally available inhibition of SCD1, leading to reduced hepatic lipids and improved glucose tolerance in insulin-resistant rat models. The drug also improved whole-body insulin sensitivity, suggesting potential utility for treating conditions like insulin resistance and related metabolic diseases[1].